Key Facts
• June 16, 2025: U.S. pharmaceutical firms increasingly license drug candidates from Chinese companies.
• Licensing deals rose from 2 in early 2024 to 14 by mid-2025.
• Total potential deal payments could reach $18.3 billion in 2025.
• U.S. firms face $200 billion worth of expiring drug patents within 10 years.
• Licensing costs: $31.3 billion (China) vs. $84.8 billion (U.S.) over 5 years.
• Pfizer paid $1.25 billion upfront for a cancer drug license from 3SBio in May 2025.
• Regeneron signed an $80 million obesity drug deal with Hansoh Pharma in June 2025.
• Chinese drug development share: 30%; U.S. share: 48% (1% drop).
• Analysts predict 40-50% of licensed assets in 2024 will originate from China.
• Licensing reduces development time and costs for U.S. firms.
• Trump administration considers tariffs on pharmaceuticals but excludes intellectual property.
• Nuvalent Bio acquired Anhart Therapeutics in 2024, gaining access to a cancer drug now U.S.-approved.
Summary
U.S. pharmaceutical companies are increasingly turning to Chinese firms for drug candidate licensing, driven by expiring patents and cost advantages. Licensing deals surged from 2 in early 2024 to 14 by mid-2025, with potential payments reaching $18.3 billion. Chinese licensing costs are significantly lower than U.S. counterparts, averaging $31.3 billion over five years compared to $84.8 billion domestically. Notable deals include Pfizer’s $1.25 billion upfront payment to 3SBio for a cancer drug and Regeneron’s $80 million agreement with Hansoh Pharma for an obesity treatment. Analysts highlight China’s growing share in global drug development, now at 30%, and predict up to 50% of licensed assets in 2024 will come from China. Licensing offers U.S. firms faster, cost-effective access to innovative treatments, reflecting China’s robust R&D investments. Despite potential U.S. tariffs on pharmaceuticals, intellectual property remains exempt, ensuring continued licensing activity. The trend underscores China’s rising influence in biopharmaceutical innovation.
